Seroba Life Sciences

Perfuze is a neurovascular medical device company based in Galway, Ireland, founded in 2018. The company focuses on developing innovative catheter technology specifically for the treatment of acute ischemic stroke. Perfuze aims to enhance clinical outcomes and reduce procedural times through its proprietary catheter-based aspiration technology, which optimizes the efficiency of clot removal. By simplifying procedures and minimizing the need for alternative treatment methods, Perfuze seeks to provide cost-effective solutions for patients suffering from ischemic stroke.

Deciphex is a digital pathology software company that blends AI with pathology expertise to streamline diagnostic workflows and support therapeutic development. Its Patholytix platform applies digital pathology and AI to preclinical and toxicologic pathology, triaging high-volume, low-complexity samples and accelerating preclinical safety assessments for pharma and clinical research. Its Diagnexia platform connects global subspecialty pathologists to deliver rapid diagnostics and reduce backlogs in clinical workflows. Founded in 2017, Deciphex is headquartered in Dublin, Ireland.

ShiraTronics develops neuromodulation therapies to treat chronic migraine by delivering continuous stimulation to targeted nerves to relieve, interrupt, and prevent migraine episodes. Founded in 2018 and based in Ireland, the company maintains an additional location in Minneapolis, Minnesota, and pursues innovative neuromodulation technology to address unmet neurological needs and improve patient outcomes.

Loci Orthopaedics Limited, established in 2017 and headquartered in Upper Newcastle, Ireland, specialises in the manufacture of medical instruments, notably the InDx implant. This innovative device is designed to mimic natural thumb joint motions and offers a less invasive surgical solution for patients with arthritis in their thumb base joint, addressing a significant unmet clinical need in orthopaedics.

Shorla Pharma Limited is an Irish specialty pharmaceutical company focused on developing and manufacturing oncology drugs for orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company aims to provide accessible and affordable life-saving treatments. Its product portfolio includes SH-111, a sterile injectable solution designed to treat T-cell leukemia in both pediatric and adult patients, as well as SH-105, another oncology drug. Shorla Pharma is dedicated to enhancing patient care and making a significant clinical impact through its innovative therapies.

Deciphex is a digital pathology software company that blends AI with pathology expertise to streamline diagnostic workflows and support therapeutic development. Its Patholytix platform applies digital pathology and AI to preclinical and toxicologic pathology, triaging high-volume, low-complexity samples and accelerating preclinical safety assessments for pharma and clinical research. Its Diagnexia platform connects global subspecialty pathologists to deliver rapid diagnostics and reduce backlogs in clinical workflows. Founded in 2017, Deciphex is headquartered in Dublin, Ireland.

Perfuze is a neurovascular medical device company based in Galway, Ireland, founded in 2018. The company focuses on developing innovative catheter technology specifically for the treatment of acute ischemic stroke. Perfuze aims to enhance clinical outcomes and reduce procedural times through its proprietary catheter-based aspiration technology, which optimizes the efficiency of clot removal. By simplifying procedures and minimizing the need for alternative treatment methods, Perfuze seeks to provide cost-effective solutions for patients suffering from ischemic stroke.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Shorla Pharma Limited is an Irish specialty pharmaceutical company focused on developing and manufacturing oncology drugs for orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company aims to provide accessible and affordable life-saving treatments. Its product portfolio includes SH-111, a sterile injectable solution designed to treat T-cell leukemia in both pediatric and adult patients, as well as SH-105, another oncology drug. Shorla Pharma is dedicated to enhancing patient care and making a significant clinical impact through its innovative therapies.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

Biosensia Ltd. is a Dublin-based company specializing in point-of-care in-vitro diagnostics. It has developed RapiPlex, an innovative diagnostic system designed to deliver both quantitative and qualitative laboratory test results. This system features a disposable assay cartridge and a compact tabletop instrument, allowing for the transition of complex immunoassays from centralized laboratories to doctors' offices or patients' bedsides. RapiPlex facilitates near-patient care by providing rapid and practical testing solutions across various applications, including theranostic identification and monitoring, as well as veterinary and food safety testing. The platform is compatible with multiple biological sample types, such as whole blood, plasma, serum, urine, saliva, and milk. Founded in 2000 and previously known as NanoComms Ltd., Biosensia Ltd. rebranded in 2006 and currently operates as a subsidiary of Kypha Inc.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

Veryan Medical Ltd. is a UK-based company that specializes in the design and development of innovative vascular stent technology. Established in 2003 as a spin-out from Imperial College London, the company focuses on its proprietary BioMimics 3D technology, which employs biomimicry principles to enhance stent performance. This technology features a unique three-dimensional helical geometry that replicates natural curvature, promoting improved blood flow dynamics and reducing the risk of complications such as restenosis. Veryan Medical's stents are particularly aimed at treating patients with symptomatic peripheral arterial disease in the lower limbs, facilitating quicker initiation of treatment and potentially leading to better health outcomes. The company operates a research and development facility in Galway, Ireland, and, as of December 2018, is a subsidiary of Otsuka Medical Devices Co., Ltd.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Biosensia Ltd. is a Dublin-based company specializing in point-of-care in-vitro diagnostics. It has developed RapiPlex, an innovative diagnostic system designed to deliver both quantitative and qualitative laboratory test results. This system features a disposable assay cartridge and a compact tabletop instrument, allowing for the transition of complex immunoassays from centralized laboratories to doctors' offices or patients' bedsides. RapiPlex facilitates near-patient care by providing rapid and practical testing solutions across various applications, including theranostic identification and monitoring, as well as veterinary and food safety testing. The platform is compatible with multiple biological sample types, such as whole blood, plasma, serum, urine, saliva, and milk. Founded in 2000 and previously known as NanoComms Ltd., Biosensia Ltd. rebranded in 2006 and currently operates as a subsidiary of Kypha Inc.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.